Certara Inc
NASDAQ:CERT

Watchlist Manager
Certara Inc Logo
Certara Inc
NASDAQ:CERT
Watchlist
Price: 10.74 USD 0.28% Market Closed
Market Cap: 1.7B USD
Have any thoughts about
Certara Inc?
Write Note

Certara Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Certara Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Certara Inc
NASDAQ:CERT
Income from Continuing Operations
-$55.4m
CAGR 3-Years
-4%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Veeva Systems Inc
NYSE:VEEV
Income from Continuing Operations
$665.9m
CAGR 3-Years
15%
CAGR 5-Years
17%
CAGR 10-Years
35%
Inspire Medical Systems Inc
NYSE:INSP
Income from Continuing Operations
$33m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Income from Continuing Operations
$147.6m
CAGR 3-Years
43%
CAGR 5-Years
80%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Income from Continuing Operations
-$17.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
Waystar Holding Corp
NASDAQ:WAY
Income from Continuing Operations
-$51.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Certara Inc
Glance View

Market Cap
1.7B USD
Industry
Health Care

Certara Inc., founded in 2008, has emerged as a pivotal player in the realm of virtual drug development, leveraging its sophisticated model-based drug development technology to transform how pharmaceutical companies strategize and optimize drug discovery. The company's core strength lies in its comprehensive suite of biosimulation software and services, which predict how drugs behave in the human body. This revolutionary approach allows pharmaceutical companies to refine their drug development processes, increase efficiency, and reduce the time and cost associated with bringing new drugs to market. By providing insights into drug interactions, efficacy, and safety, Certara aids its clients in making informed decisions early in the development cycle, essentially becoming an indispensable ally in navigating the complex and costly landscape of drug development. Certara generates revenue primarily through software licensing and consulting services, establishing long-term partnerships with its diverse clientele, which includes over 1,850 companies worldwide, including prominent pharmaceutical giants and regulatory agencies. By embedding itself into the critical processes of drug development, Certara garners not just the upfront licensing fees but also ongoing consulting fees that allow pharmaceutical companies to fine-tune and optimize their drug development strategies continuously. As healthcare industries place increasing emphasis on precision medicine and personalized healthcare, Certara's role as a guide in these innovations becomes even more pronounced, ensuring its financial health and relevance in a highly competitive field. The company's growth reflects a keen understanding of its niche, capitalizing on its unique offerings to remain at the forefront of scientific innovation.

CERT Intrinsic Value
11.44 USD
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Certara Inc's Income from Continuing Operations?
Income from Continuing Operations
-55.4m USD

Based on the financial report for Dec 31, 2023, Certara Inc's Income from Continuing Operations amounts to -55.4m USD.

What is Certara Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-11%

The average annual Income from Continuing Operations growth rates for Certara Inc have been -4% over the past three years , -11% over the past five years .

Back to Top